Le Lézard
Classified in: Health
Subject: FDA

Blood Flow Monitoring Device - FlowMet-R Gets FDA 510K Clearance

IRVINE, Calif., Oct. 2, 2019 /PRNewswire/ -- Laser Associated Sciences (LAS), a medical device company based in Irvine, California, announced that its blood flow monitoring system, FlowMet-R, received its 510(k) clearance from the Food and Drug Administration (FDA). This clearance allows LAS to market and sell the FlowMet-R. The non-invasive portable device addresses a critical unmet need for vascular specialists who are seeking improved methods to detect and measure treatment efficacy for peripheral artery disease (PAD). The condition, which according to the American Heart Association, affects over 200 million people worldwide, often goes undiagnosed and when left untreated, can result in amputation.

The FlowMet-R is simple for clinicians to use as the device is compact and clips directly onto a patient's toe. The technology includes a small laser diode and a camera the size of a postage stamp to measure blood flow in the digit in real time. This measurement reflects the severity of vascular disease upstream of the digit. Vascular clinicians who use FlowMet-R believe it fills an essential need via intraprocedural monitoring, enabling them to make better decisions about their treatment during surgery.

"By directly measuring limb perfusion during surgeries, physicians can see for the first time whether peripheral blood flow in being improved in real time. This reduces the ambiguity that clinicians currently face in knowing not only if an intervention is effective, but how effective it is. It is inspiring for us to receive such positive feedback from both the medical community and receive clearance from the FDA so quickly," says Sean White, CEO of LAS. 

The company also recently completed a clinical study in which FlowMet-R measurements demonstrated improved accuracy in detecting advanced vascular disease compared to standard vascular assessments. "The results were very impactful toward improving patient care, and we look forward to publishing the results shortly," adds White.

LAS continues to collaborate with clinicians to develop new technologies that will improve outcomes for patients. The company is also exploring opportunities to build products for home use as well.

About Laser Associated Sciences

Laser Associated Sciences is a medical device company based in Irvine, California. The company's mission is to provide users with critical and impactful information by developing optical biometric sensors and non-invasive medical devices for healthcare applications. In addition to selling and marketing its flagship product, FlowMet-R, LAS is developing additional innovative solutions for the medical community and consumers.  

Samantha McDermott
(760) 671-0071

SOURCE Laser Associated Sciences

These press releases may also interest you

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

at 10:10
Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral...

at 09:35
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019...

at 09:33
Oncopeptides AB  will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with...

News published on 2 october 2019 at 08:12 and distributed by: